SEC Filings

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. We leverage our deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer.

Our innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The first antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism, currently progressing in multiple indications in collaboration with GSK. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression into proof-of concept trials in several indications following encouraging single-agent activity in Phase 1.

iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

For investors

Discover more about iTeos Therapeutics, our science, and our high potential for investment.

SEC Filings

Filing date Form Description Filing Group View
SC 13D/A

An amendment to a SC 13D filing

Other
View HTML
4

Statement of changes in beneficial ownership of securities

3,4,5
View HTML
SC 13D/A

An amendment to a SC 13D filing

Other
View HTML
8-K

Report of unscheduled material events or corporate event

Current Reports
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q

Quarterly report which provides a continuing view of a company's financial position

Quarterly Filings
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

Registration Statements
View HTML
DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

Proxy Filings
View HTML
DEFA14A

Additional proxy soliciting materials - definitive

Proxy Filings
View HTML
ARS

An annual report to security holders

Annual Filings
View HTML
4

Statement of changes in beneficial ownership of securities

3,4,5
View HTML

Data provided by Kaleidoscope.

Cancer Cells graphics

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.

Driven by a culture of scientific innovation, collaboration and excellence, together we discover and deliver breakthrough immunotherapies to improve and extend the lives of people with cancer.